AbbVie (ABBV) Q3 2025 Earnings
AbbVie reported Q3 2025 revenue of $15.8B (+9.1% YoY), beat analyst consensus of $15.6B by $190.2M. Diluted EPS came in at $1.86 (-38.0% YoY), beat the $1.77 consensus by $0.09. AbbVie reports across 2 business segments, led by Biopharmaceutical Products and Aesthetics.
Financial Snapshot
Trailing eight quarters through Q3 2025
Q3 2025 Earnings FAQ
Common questions about AbbVie's Q3 2025 earnings report.
AbbVie (ABBV) reported Q3 2025 earnings on October 31, 2025 before market open.
AbbVie reported revenue of $15.8B and diluted EPS of $1.86 for Q3 2025.
Revenue beat the consensus estimate of $15.6B by $190.2M. EPS beat the consensus estimate of $1.77 by $0.09.
Compared to the same quarter a year prior, revenue grew 9.1% from $14.5B a year earlier and diluted EPS declined 38.0% from $3.00.
You can read the 10-Q periodic report (0001551152-25-000049) directly on SEC EDGAR. The filing index links above go to sec.gov.